Confocal microscopy of idarubicin localisation in sensitive and multidrug-resistant bladder cancer cell lines

British Journal of Cancer

Volumn 74, Issue 6, 1996, Pages 906-909

  Duffy, P M ^a,b   Hayes, M C ^a   Cooper, A ^a   Smart, C J ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Bladder cancer; Confocal microscopy; Epirubicin; Idarubicin; Multidrug resistance; Verapamil

Indexed keywords

ANTHRACYCLINE; IDARUBICIN; VERAPAMIL;

ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; HUMAN; HUMAN CELL; LIPOPHILICITY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

EID: 0029781044     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.455     Document Type: Article

References (13)

1. BERMAN E AND MCBRIDE M. (1992). Comparative cellular pharmacology of daunorubicin and idarubicin in human multi-drug-resistant leukaemia cells. Blood, 12, 3267-3273.
2. COLEY HM, AMOS PR, TWENTYMAN PR AND WORKMAN P. (1993). Examination by confocal fluorescence imaging micro-scopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines. Br. J. Cancer, 67, 1316-1323.
3. DUFFY PM, HAYES MC, GATRELL SKE, COOPER A AND SMART CJ. (1996). Determination and reversal of resistance to epirubicin intravesical chemotherapy. A confocal imaging study. Br. J. Urol., 77(6), 824-829.
4. FLOYD JW, LIN C AND PROUT GR. (1990). Multi-drug resistance of a doxorubicin-resistant bladder cancer cell line. J. Urol., 144, 169-171.
5. FRESHNEY RI. (1994). Culture of Animal Cells. A Manual of Basic Technique. pp. 296-298. Wiley-Liss: New York.
6. GERVASONI JE, FIELDS SZ, KRISHNA S, BAKER MA, ROSADO M, THURAISAMY K, HINDENBURG AA AND TAUB RN. (1991). Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy. Cancer Res., 51, 4955-4963.
7. AD cells and its relation to cellular drug localisation. Biochim. Biophys. Acta, 1093, 147-152.
8. MICHIELI M, DAMIANI D, MICHELUTTI A, CANDONI A, MASOLINI P, SCAGGIANTE B, QUADRIFOGLIO F AND BACCARANI M. (1994). Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833. Haematologica, 79, 500-507.
9. MOSCOW JA, SCHNEIDER E AND COWAN KH. (1993). Multidrug resistance. In Cancer Chemotherapy and Biological Response Modifiers, Pinedo HM, Longo DL, Chabner BA (eds). Annual 14, pp. 98-117. Elsevier Science: Oxford.
10. PLOSKER GL AND FAULDS D. (1993). Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in cancer chemotherapy. Drugs, 45, 788-856.
11. ROEPE PD. (1992). Analysis of the steady-state and initial rate of doxorubicin efflux from a series of multi-drug resistant cells expressing different levels of P-glycoprotein. Biochemistry, 31, 12555-12564.
12. SCHEFFER GL, WIJNGAARD PLJ, FLENS MJ, IZQUIERDO MA, SLOVAK ML, PINEDO HM, MEIJER CJ, CLEVERS HC AND SCHEPER RJ. (1995). The drug resistance-related protein LRP is the human major vault protein. Nature Med., 1, 578-582.
13. ZAMAN GJR, FLENS MJ, VAN LEUSDEN MR, DE HAAS M, MÜLDER HS, LANKELMA J, PINEDO HM, SCHELPER RJ, BAAS F, BROXTERMAN JH AND BORST P. (1994). The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc. Natl Acad. Sci. USA, 91, 8822-8826.